Editor's Note
Just a week after Pfizer revealed an interim analysis showing its COVID-19 vaccine to be more than 90% effective, the company on November 18 released its final efficacy analysis showing the vaccine is 95% effective, and that it protects older people who are most at risk of dying from COVID-19.
Pfizer and German partner BioNTech say they have reached a safety milestone that will allow them to apply for a Food and Drug Administration (FDA) emergency use authorization (EUA) within days.
On November 16, Moderna announced that an interim analysis of its COVID-19 vaccine showed it to be 94.5% effective. The Moderna and Pfizer vaccines are both mRNA based and require two doses.
Read More >>Takeaways • The 3A Strategic Thinking Framework and the GOST…
How should responsibilities associated with C-sections be divided between the…
Reliable and robust enough for daily use on most medical…